Robert Wespiser
Internal Medicine · Lee, MANPI 1295783819
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 147 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $679 and has fallen 97.5% since, to $17 in 2023.
Across 147 payments — averaging $15.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$348
- AstraZeneca$261
- Pfizer$220
- Johnson & Johnson$195
- Novo Nordisk$125
- Lilly USA, LLC$121
- plus $983 from 17 others
What the payments were for
- Food & beverage$2,24099%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 34 | $348 |
| AstraZeneca | 15 | $261 |
| Pfizer | 13 | $220 |
| Johnson & Johnson(2 entities) | 14 | $195 |
| Novo Nordisk | 8 | $125 |
| Lilly USA, LLC | 7 | $121 |
| Novartis | 7 | $119 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $92 |
| Boehringer Ingelheim | 6 | $91 |
| Merck | 6 | $87 |
| Sunovion Pharmaceuticals Inc. | 4 | $68 |
| Nestle Healthcare Nutrition Inc. | 3 | $68 |
| E.r. Squibb & Sons, L.L.C. | 4 | $68 |
| Astellas Pharma US Inc | 3 | $62 |
| Amgen | 3 | $57 |
| Avanir Pharmaceuticals, Inc. | 2 | $52 |
| Biohaven Pharmaceuticals, Inc. | 3 | $44 |
| Abbott | 2 | $37 |
| Bioventus LLC | 3 | $35 |
| Scilex Pharmaceuticals Inc. | 3 | $34 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Amarin Pharma, Inc. | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $21 |
How this compares
$2,252 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ziprasidone Hcl | 13 | $1,906 |
| Oxcarbazepine | 12 | $1,835 |
| Mirtazapine | 34 | $748 |
| Finasteride | 23 | $591 |
| Tamsulosin Hcl | 22 | $548 |
| Haloperidol Lactate | 11 | $495 |
| Divalproex Sodium | 13 | $442 |
| Famotidine | 14 | $434 |
| Fluoxetine Hcl | 30 | $352 |
| Sertraline Hcl | 20 | $292 |
| Lisinopril | 12 | $267 |
| Levothyroxine Sodium | 19 | $259 |
| Atorvastatin Calcium | 12 | $204 |
| Primidone | 18 | $181 |
| Benztropine Mesylate | 13 | $169 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Lee
- David SchenkeinBoston$5M
- Alan GarberCambridge$4.9M
- John FallonBoston$1.8M
- Michael MendelsohnBoston$1.6M
- Sandra RichmanBrookline$1.4M
- Gaurav SingalBoston$798K
- Asit ParikhBoston$486K
- Noopur RajeBoston$481K
- Daniel KuritzkesBoston$443K
- Xiuning leBoston$364K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.